Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07366554

Epigenetic Factors of Colorectal Adenoma in Korean

This study aims to explore epigenetic factors associated with colorectal adenoma (CRA) in the Korean population. CRA is a key precancerous lesion in the adenoma-carcinoma sequence, and identifying methylated genetic markers may improve early detection and risk stratification for colorectal cancer (CRC).

A total of 32 patients undergoing colonoscopic polypectomy will be enrolled. Adenomatous and adjacent normal tissues will be collected for deoxyribonucleic acid (DNA) extraction and bisulfite conversion. Quantitative methylation-specific polymerase chain reaction (qMSP) and Sanger sequencing will be used to assess the methylation status of candidate genes (SFRP2, TFPI2, SEPT9, and SDC2). Stool samples will also be analyzed by whole-genome sequencing (WGS) to evaluate microbiome and genetic profiles.

The study seeks to determine whether methylation levels of these genes are significantly elevated in adenoma tissue compared with normal mucosa, thereby identifying potential biomarkers for colorectal neoplasia surveillance and personalized colonoscopy follow-up intervals.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

19 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Colorectal cancer (CRC) is one of the most common malignancies in Korea, ranking second in national cancer incidence statistics. Most CRCs arise through the adenoma-carcinoma sequence, in which epigenetic and genetic alterations play critical roles. Identifying methylated genetic markers in colorectal adenoma may provide insights into early carcinogenic mechanisms and enable more individualized surveillance strategies after polypectomy.

This study focuses on exploring epigenetic factors-particularly DNA methylation patterns-associated with colorectal adenoma in Korean patients. A total of 32 participants undergoing colonoscopic polypectomy will be recruited. From each participant, both adenomatous tissue and adjacent normal mucosa (approximately 5 millimeters (mm) in size) will be collected. Stool samples will also be obtained for microbiome and genomic analysis.

DNA extracted from tissue and stool samples will undergo bisulfite conversion using the EZ DNA Methylation-Gold Kit (Zymo Research). Quantitative methylation-specific polymerase chain reaction (qMSP) will be performed to evaluate promoter methylation levels of four candidate genes-SFRP2 (Secreted Frizzled Related Protein 2), TFPI2 (Tissue Factor Pathway Inhibitor 2), SEPT9 (Septin 9), and SDC2 (Syndecan 2)-that have previously shown potential as colorectal neoplasia biomarkers. Selected samples will also undergo Sanger sequencing for CpG-level methylation profiling. Stool DNA will be analyzed through whole-genome sequencing (WGS) on the Illumina NovaSeq 6000 platform to assess microbial composition and genetic context.

Methylation indices (MtI) and percentage of methylated reference (PMR) values will be calculated and compared between adenoma and adjacent normal tissues. Receiver operating characteristic (ROC) curve analysis will determine the sensitivity and specificity of each gene as a potential biomarker.

By identifying methylated genes that are significantly upregulated in adenomatous tissues, this study aims to propose candidate epigenetic markers for predicting the recurrence or malignant transformation of colorectal adenoma. The findings may contribute to refining post-polypectomy surveillance intervals and supporting precision prevention strategies in CRC.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

  • Inclusion Criteria:
  • Adults aged 19-85 years
  • Undergoing colonoscopic polypectomy for colorectal adenoma
  • Able to understand the study purpose and provide written informed consent
  • Adequate tissue available for both adenoma and adjacent normal mucosa sampling
  • Exclusion Criteria:
  • History of colorectal cancer, inflammatory bowel disease, or hereditary colorectal cancer syndrome (e.g., FAP, Lynch syndrome)
  • Previous colorectal surgery that may alter anatomy or pathology
  • Inadequate sample quality or failure of DNA extraction
  • Refusal or withdrawal of informed consent
  • Severe comorbidities that make participation unsuitable at investigator's discretion

Treatment and study plan

Primary outcomes

  1. Methylation index of SFRP2 in colorectal tissue

    Time frame: Baseline (Single Time Point)]

    Quantitative assessment of DNA methylation levels in adenomatous versus adjacent normal colorectal tissues. Methylation levels will be determined using quantitative methylation-specific PCR (qMSP) and expressed as methylation index (MtI, %).

  2. Methylation index of TFPI2 in colorectal tissue

    Time frame: Baseline (Single Time Point)]

    Quantitative assessment of DNA methylation levels in adenomatous versus adjacent normal colorectal tissues. Methylation levels will be determined using quantitative methylation-specific PCR (qMSP) and expressed as methylation index (MtI, %).

  3. Methylation index of SEPT9 in colorectal tissue

    Time frame: Baseline (Single Time Point)]

    Quantitative assessment of DNA methylation levels in adenomatous versus adjacent normal colorectal tissues. Methylation levels will be determined using quantitative methylation-specific PCR (qMSP) and expressed as methylation index (MtI, %).

  4. Methylation index of SDC2 in colorectal tissue

    Time frame: Baseline (Single Time Point)]

    Quantitative assessment of DNA methylation levels in adenomatous versus adjacent normal colorectal tissues. Methylation levels will be determined using quantitative methylation-specific PCR (qMSP) and expressed as methylation index (MtI, %).

Secondary outcomes

  1. Sensitivity and specificity of methylated SFRP2 for detecting adenoma

    Time frame: Baseline (Single Time Point)

    Receiver operating characteristic (ROC) curve analysis will be used to evaluate the diagnostic performance of methylated SFRP2 in distinguishing adenomatous from normal tissue. The percentage of methylated reference (PMR) values derived from qMSP will be compared between groups.

  2. Sensitivity and specificity of methylated TFPI2 for detecting adenoma

    Time frame: Baseline (Single Time Point)

    Receiver operating characteristic (ROC) curve analysis will be used to evaluate the diagnostic performance of methylated TFPI2 in distinguishing adenomatous from normal tissue. The percentage of methylated reference (PMR) values derived from qMSP will be compared between groups.

  3. Sensitivity and specificity of methylated SEPT9 for detecting adenoma

    Time frame: Baseline (Single Time Point)

    Receiver operating characteristic (ROC) curve analysis will be used to evaluate the diagnostic performance of methylated SEPT9 in distinguishing adenomatous from normal tissue. The percentage of methylated reference (PMR) values derived from qMSP will be compared between groups.

  4. Sensitivity and specificity of methylated SDC2 for detecting adenoma

    Time frame: Baseline (Single Time Point)

    Receiver operating characteristic (ROC) curve analysis will be used to evaluate the diagnostic performance of methylated SDC2 in distinguishing adenomatous from normal tissue. The percentage of methylated reference (PMR) values derived from qMSP will be compared between groups.

Study contacts

Contact information is provided by the study sponsor or research team.

OneJoong KIM, M.D.

CONTACT

[email protected]

82+010+2111+0415

Sponsors and collaborators

Lead sponsor

Bundang CHA Hospital

Other

Registry information

Official study title

Exploration of Epigenetic Factors of Colorectal Adenoma in Korean

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Jan 26, 2026
Registry last updated
Jan 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.